The place for (tech) startups! Click here for our offer in ALPHA

New website AmbAgon live


Good news for those interested in AmbAgon's screening technologies: as of this week, their new website is live! 

This American-Dutch medtech company, based at Twice hub Catalyst in Eindhoven and in San Francisco, discovered a new approach to drug development for metastatic breast cancer with its innovative research on stabilization of protein-protein interactions. A groundbreaking method that is changing the future of cancer patients and their compliance.

AmbAgon has developed small-molecule screening technologies aimed at discovering molecules that stabilize the direct interaction of oncogenic transcription factors with so-called 14-3-3 proteins, thereby inhibiting their pathological activities. This approach, to enhance the endogenous tumor-suppressive functions of 14-3-3 within different types of breast cancer with small molecule drugs, provides a radically new entry. A method long sought by the pharmaceutical industry and much needed in the clinic. 

Ambagon's platform approach also opens up opportunities to address other important unmet clinical needs.

To the website of AmbAgon